The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

Knowledge of the association between human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma (OPSCC) is poor and ...

Head and neck squamous cell carcinoma (HNSCC), the seventh most prevalent cancer globally, originates from the mucosal epithelium of the oral cavity, pharynx, and larynx. Traditional risk factors like ...

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

The recommended commercial dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks. Cutaneous squamous cell carcinoma (cSCC) is the second most common ...

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...

ESPN analyst Randy Moss, who retired from the NFL in 2012 after 14 seasons, revealed that he is a “cancer survivor” and will ...

First-of-its-kind research looking at survival rates for patients with incurable larynx cancer has been published.

A year after manufacturing issues resulted in a complete response letter for cosibelimab, the U.S. FDA approved Checkpoint Therapeutics Inc.’s drug, branded Unloxcyt, as the first anti-PD-L1 antibody ...

The U.S Food and Drug Administration said on Friday it has approved Checkpoint Therapeutics' drug for treatment of a type of ...